<DOC>
	<DOCNO>NCT01599637</DOCNO>
	<brief_summary>The study design explore mode action omalizumab therapy patient chronic idiopathic urticaria .</brief_summary>
	<brief_title>Mode Action Study Omalizumab Patients With Chronic Idiopathic Urticaria ( CIU ) Who Fail Respond Antihistamine Treatment</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<mesh_term>Histamine Antagonists</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<criteria>Diagnosis chronic spontaneous urticaria refractory H1 antihistamines Baseline Clearly define underlie etiology chronic urticarias CIU ( main manifestation physical urticaria ) . This include follow urticaria : Acute , solar , cholinergic , heat , cold , aquagenic , delayed pressure contact , well follow disease disease may symptoms urticaria angioedema : Urticarial vasculitis , urticaria pigmentosa , erythema multiforme , mastocytosis , hereditary acquire angioedema , lymphoma , leukemia , generalized cancer . Previous treatment omalizumab . A history presence atopic dermatitis , bullous pemphigoid , dermatitis herpetiformis , senile pruritus skin disease associate itch . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Chronic idiopathic urticaria</keyword>
	<keyword>CIU</keyword>
	<keyword>Xolair</keyword>
	<keyword>IGE025</keyword>
	<keyword>FcÎµRI</keyword>
	<keyword>IgE</keyword>
</DOC>